Floatz logo

ARA-GUANOSINE

PASC Post Acute Sequelae of COVID-19

University of California, DavisSmall moleculeEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the PASC Post Acute Sequelae of COVID-19 cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

ARA-GUANOSINE is also rated in:

Alzheimer Disease (AD)Dormant
CCC
Indicative ·
52 / 100
View asset →
Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT BenefitDormant
CCC
Indicative ·
52 / 100
View asset →
Non-small Cell Lung CancerDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →